Aspira Women’s Health Inc. (NASDAQ:AWH) Sees Significant Growth in Short Interest

Aspira Women’s Health Inc. (NASDAQ:AWH) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 537,600 shares, an increase of 20.4% from the October 15th total of 446,600 shares. Approximately 4.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 100,200 shares, the days-to-cover ratio is currently 5.4 days.

Analysts Set New Price Targets

A number of research firms recently issued reports on AWH. StockNews.com started coverage on Aspira Women’s Health in a report on Wednesday. They set a “hold” rating on the stock. Alliance Global Partners dropped their target price on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a report on Wednesday, August 14th.

Aspira Women’s Health Trading Up 1.3 %

Shares of NASDAQ AWH traded up $0.01 during mid-day trading on Friday, reaching $0.75. The company had a trading volume of 43,333 shares, compared to its average volume of 141,662. Aspira Women’s Health has a 1-year low of $0.72 and a 1-year high of $5.65. The stock has a market cap of $12.04 million, a PE ratio of -0.52 and a beta of 1.44. The company has a 50-day moving average price of $0.85 and a two-hundred day moving average price of $1.41.

Institutional Trading of Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its position in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. 12.19% of the stock is owned by institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.